Diagnosis and Treatment of Pulmonary Arterial Hypertension

医学 西地那非 曲前列环素 肺动脉高压 安倍生坦 波生坦 肺动脉 内科学 心脏病学 肺楔压 血管阻力 心力衰竭 环磷酸鸟苷 他达拉非 里奥西瓜特 血压 一氧化氮 内皮素受体 慢性血栓栓塞性肺高压 受体
作者
Nicole F. Ruopp,Barbara A. Cockrill
出处
期刊:JAMA [American Medical Association]
卷期号:327 (14): 1379-1379 被引量:278
标识
DOI:10.1001/jama.2022.4402
摘要

Importance

Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death.

Observations

Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide–cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide–cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy.

Conclusions and Relevance

Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助LJJ采纳,获得10
1秒前
1秒前
1秒前
non平行线完成签到,获得积分10
2秒前
惜名发布了新的文献求助10
5秒前
6秒前
生动的芝发布了新的文献求助10
6秒前
memedaaaah完成签到,获得积分10
8秒前
FashionBoy应助柔弱狗采纳,获得10
9秒前
lanshi1008发布了新的文献求助10
12秒前
华仔应助搞怪夏天采纳,获得10
13秒前
15秒前
Owen应助远方的蓝风铃采纳,获得10
16秒前
希望天下0贩的0应助惜名采纳,获得10
16秒前
16秒前
17秒前
18秒前
18秒前
完美世界应助科研通管家采纳,获得10
18秒前
科研通AI2S应助科研通管家采纳,获得10
18秒前
SciGPT应助科研通管家采纳,获得10
18秒前
香蕉觅云应助科研通管家采纳,获得10
18秒前
丘比特应助科研通管家采纳,获得10
19秒前
淡然安雁应助科研通管家采纳,获得10
19秒前
英俊的铭应助科研通管家采纳,获得10
19秒前
赘婿应助科研通管家采纳,获得10
19秒前
19秒前
CC发布了新的文献求助10
21秒前
21秒前
慕青应助小晋采纳,获得10
23秒前
顾矜应助sherry221采纳,获得10
25秒前
不配.应助乖乖隆地洞采纳,获得10
25秒前
顾矜应助haveatry采纳,获得10
26秒前
MrHwc发布了新的文献求助10
27秒前
SciGPT应助凉拌冰阔落采纳,获得10
27秒前
27秒前
29秒前
29秒前
葵魁发布了新的文献求助10
29秒前
29秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3141258
求助须知:如何正确求助?哪些是违规求助? 2792257
关于积分的说明 7801943
捐赠科研通 2448459
什么是DOI,文献DOI怎么找? 1302536
科研通“疑难数据库(出版商)”最低求助积分说明 626638
版权声明 601237